Navigation Links
AGA presents cutting-edge research during DDW

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week 2010 (DDW), the largest and most prestigious gastroenterology meeting, from May 1 to May 5, 2010, at the Ernest N. Morial Convention Center, New Orleans, LA. DDW is the annual meeting of the American Gastroenterological Association (AGA) Institute, the largest and oldest GI society in the world. AGA researchers will present exciting, cutting-edge data during the meeting that will help change the way physicians diagnose and treat GI disorders.

All data presented during DDW is embargoed until the beginning of the presentation or an official DDW press conference, whichever occurs first. Go to for a list of press conferences.

Late-Breaking Session

On Tuesday, May 4 from 2:15 to 3:45 p.m. CT, Ballroom C, the AGA will feature its late-breaking clinical abstracts, which include exciting data on:

  • A Randomized Placebo-controlled Trial of MDX-1100, an Anti-IP-10 Antibody, for Moderately-to-Severely Active Ulcerative Colitis. L. Mayer et al. (2:15 p.m.)
  • Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide plus Peginterferon and Ribavirin in Nave Patients with Chronic Hepatitis C Genotype 1 Infection: Final Report. B. Bacon et al. (2:30 p.m.)
  • Randomized Clinical Trial in Clostridium difficile Infection Confirms Superiority of Fidaxomicin over Vancomycin. S. Johnson et al. (2:45 p.m.)
  • Prospective Clinical Validation of an Assay for Methylated SEPT9 DNA in Human Plasma as a Colorectal Cancer Screening Tool in Average Risk Men and Women 50 Years and Older. T. Church et al. (3:00 p.m.)
  • A Prospective, Multicentre Study to Evaluate a Novel Non-Endoscopic Screening Device for Barrett's Esophagus in the Community Setting. S. Kadri et al. (3:15 p.m.)
  • Multi-Modality Endoscopic Therapy for Complete Eradication of Barrett's Esophagus. N. Gupta et al. (3:30 p.m.)

Plenary Sessions

During the Presidential Plenary Session, AGA Institute President, Gail A. Hecht, MD, MS, AGAF, will focus on critical questions for gastroenterology. Two concurrent plenary sessions feature noteworthy clinical and basic science research presented at DDW.

The Presidential Plenary session presentations (Monday, May 3, 10 a.m. to noon CT, Auditorium AB) include:

  • Celiac Disease Therapy and Novel Approaches. C. Kelly (10:09 a.m.)
  • Evaluating IBD: Outcomes and Complications. M. Abreu (10:19 a.m.)
  • Major Advances in IBS. L. Chang (10:29 a.m.)
  • Eosinophilic Esophagitis: Challenges and Horizons. G. Furuta (10:39 a.m.)
  • Gastric Disease in the 21st Century: A Tale of Three Stomachs. T. Wang (10:49 a.m.)
  • Microbiota in Digestive Health Promise, Prospects and Pragmatism. F. Shanahan (10:59 a.m.)
  • Obesity and Bariatrics for the Endoscopist: New Techniques. C. Thompson (11:09 a.m.)
  • Medical Management of NAFLD. A. Diehl (11:19 a.m.)
  • Era of Health-care Reform: What Is the Impact on GI? J. Inadomi (11:29 a.m.)

The Clinical Plenary session presentations (Monday, May 3, 8 to 10 a.m. CT, Auditorium AB) include:

  • UK Flexible Sigmoidoscopy Screening Trial: Colorectal Cancer Incidence and Mortality Rates at 11 Years After a Single Screening Examination. W. Atkin et al. (8:05 a.m.)
  • Laparoscopic Antireflux Surgery vs Long-Term Esomeprazole Treatment for Chronic GERD. Final Results After 5 Yrs of Follow up in the Lotus Study. J.P. Galmiche et al. (8:20 a.m.)
  • The European Achalasia Trial: A Randomized Multi-Centre Trial Comparing Endoscopic Pneumodilation and Laparoscopic Myotomy As Primary Treatment of Idiopathic Achalasia. G. Boeckxstaens et al. (8:35 a.m.)
  • Efficacy and Safety of Once Daily Linaclotide Administered Orally for 12-Weeks in Patients With Chronic Constipation: Results From 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials. A. Lembo et al. (8:50 a.m.)

The Basic Science Plenary session presentations (Monday, May 3, 8 to 10 a.m. CT, Room 393-396) include:

  • Altered Gut Microbiota in Toll-Like Receptor-5 (TLR5) Deficient Mice Results in Metabolic Syndrome. M. Vijay-Kumar et al. (8:05 a.m.)
  • Leptin Resistance in Vagal Afferent Neurons Leads to Decreased Cholecystokinin Signaling in Diet-Induced Obese Rats. G. de Lartigue et al. (8:22 a.m.)
  • Regulation of Food Intake in Diet-Induced Obesity. L. Kaplan (8:39 a.m.)
  • Characterization of Slowly Cycling Telomerase-Expressing Intestinal Stem Cells. C. Richmond et al. (9:04 a.m.)
  • The Crohn's Disease Protective SNP Rs11209026 Allele "a" Mediates Alternative Splicing in Human IL23R Transcription. R. Yu et al. (9:21 a.m.)

Other exciting data will be presented during DDW, including 36 clinical symposia, 11 translational symposia, 14 research symposia and eight state-of-the-art lectures on a range of GI topics. Additionally, the AGA Institute will sponsor eight curbside consultant sessions. Eight focused research roundtables and 14 focused clinical updates breakfast sessions designed to help participants choose the must-see basic science and clinical research abstracts presented during DDW will occur throughout the meeting.

AGA Digestive Health Outcomes Registry

DDW marks the launch of the AGA Digestive Health Outcomes Registry, a revolutionary national outcomes-driven registry. It allows gastroenterologists to monitor and improve patient care, while also generating data to compare the efficacy of treatments and potentially increase reimbursement. The AGA Registry launches with an initial focus on IBD and colorectal cancer prevention.

On Wednesday, May 5, from 8:30 to 10 a.m., the physicians who created the registry will lead a session in rooms 280-282 to cover topics, including what is a data registry and why participate, limits and potential pitfalls of a data registry, registry reports, and how registries can impact public health of underrepresented populations.

ROME Foundation-AGA Institute Lectureship

Erwin G. Zoetendal, MD, assistant professor in the agrotechnology and food sciences laboratory of microbiology at Wageningen University, the Netherlands, will shed light on the mysteries of gut microbiota as the invited lecturer during Tuesday's third annual Rome Foundation-AGA Institute Lectureship (10:30 to 11:30 a.m. CT, Room 391/392). His talk, "Understanding Gut Microbiota: A New Era in Gastroenterology," will provide an overview of gastrointestinal tract microbiota diversity by discussing culture-independent approaches to study microbiota diversity in relation to health and disease including functional gastrointestinal disorders as well as culture-independent approaches to study microbiota genetic potential and activity.

Douglas Drossman, MD, AGAF, Rome Foundation president, said the Rome Foundation and the AGA Institute are honored to have Dr. Zoetendal present this year's lecture. "There are huge numbers of bacteria living in harmony within every human organism. And this is the guy who understands best how different types affect the gut inside and out. He is a translational scientist who will help our members better understand when to use probiotics and when not to."


Contact: Alissa J. Cruz
American Gastroenterological Association

Related medicine news :

1. Nautilus Presents New Drivers' License Parsing Component, a Magic Tool for Software Developers
2. Presents "Marijuana & Money"
3. Presents Their Inaugural 'Carolina Beach Bash' to Benefit the Juvenile Diabetes Research Foundation
4. Morehead Presents Webinar on “When Engagement Isn't Enough: Retaining RNs”
5. Atlanta Group Presents Issues in Business Psychology at National Conference
6. PDA Presents the Facts on Braces
7. Researcher presents risk-free treatment for low female sexual desire
8. Welsh Tree LLC Proudly Presents the Release of the Celtic Pathways CD by Jason Evans, in Time for Saint Patrick's Day
9. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
10. Keynote Speaker Presents Top Business Plan For Internal Communication Through Social Media
11. Targeting leukemia cells gene addiction presents new strategy for treatment
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women ... healthcare organizations in the country. They have overseen financial turnarounds, shown commitment to ... the healthcare industry as a whole through their advocacy and professional efforts. , ...
(Date:11/26/2015)... ... 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday sales ... Black Friday and Cyber Monday massage chair sales to receive the best ... low to find the best massage chair deals, they can see all of the ...
(Date:11/26/2015)... ... ... PRMA Plastic Surgery is updating their record books yet again with an ... breast reconstruction surgery! , “What an accomplishment for the PRMA team, says Dr. ... an honor to have served all of these women.” , PRMA is one of ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY ... products, continues to provide evidence demonstrating the accuracy of ... World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease ... that both the Company,s GLUCOCARD ® 01 meter ... high accuracy requirements. The ability to accurately measure glucose ...
(Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
Breaking Medicine Technology: